Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

ORIGINAL ARTICLE

Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer

Mrabti Hind, la Fouchardiere Christelle De, Desseigne Francoise, Dussart Sophie, Negrier Sylvie, Errihani Hassan

Year : 2009| Volume: 5| Issue : 4 | Page no: 272-276

   This article has been cited by
 
1 Impact of cetuximab in current treatment of metastatic colorectal cancer
Miguel Jhonatan Sotelo Lezama,Javier Sastre Valera,Eduardo Díaz-Rubio García
Expert Opinion on Biological Therapy. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
2 Alternate dosing of cetuximab for patients with metastatic colorectal cancer
Hubbard, J.M. and Alberts, S.R.
Gastrointestinal Cancer Research. 2013; 6(2): 47-55
[Pubmed]  [Google Scholar]
3 Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer
Paolo Bossi,Gabriela Kornek,Gaetano Lanzetta,Antonio Rozzi,Thorsten Füreder,Laura Locati,Lisa Licitra
Head & Neck. 2012; : n/a
[Pubmed]  [Google Scholar] [DOI]
4 Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome
Jesús García-Foncillas,Eduardo Díaz-Rubio
Clinical and Translational Oncology. 2010; 12(8): 533
[Pubmed]  [Google Scholar] [DOI]
5 Research Highlights
Karen-Lise Garm Spindler,Anders Jakobsen
Pharmacogenomics. 2010; 11(8): 1049
[Pubmed]  [Google Scholar] [DOI]
6 Biomarkers for cetuximab: A complex pattern and need for validation
[No author name available]
Pharmacogenomics. 2010; 11(8): 1051-1052
[Pubmed]  [Google Scholar]
7 Progress in metastatic colorectal cancer: Growing role of cetuximab to optimize clinical outcome
García-Foncillas, J., Díaz-Rubio, E.
Clinical and Translational Oncology. 2010; 12(8): 533-542
[Pubmed]  [Google Scholar]

 

Read this article